Celgene to Pay $280 Million to Settle Fraud Suit Over Cancer Drugs by KATIE THOMAS


The lawsuit accused the pharmaceutical company of marketing Thalomid and Revlimid for unapproved use on a broader range of cancers.

Published: July 25, 2017 at 02:00AM

from NYT Health https://ift.tt/2uvw3P1